• Explore /
  • Poster
  • / CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).

CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

Arpit Rao

Arpit Rao

Masonic Comprehensive Cancer Center, University of Minnesota, Minneapolis, MN

Arpit Rao , Charles J. Ryan , David James VanderWeele , Glenn Heller , Lionel D Lewis , Colleen Watt , Ronald C. Chen , Robert Grubb , Olwen Mary Hahn , Himisha Beltran , Michael J. Morris

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session: Advanced Prostate Cancer

Track

Prostate Cancer - Advanced

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04455750

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr TPS181)

DOI

10.1200/JCO.2021.39.6_suppl.TPS181

Abstract #

TPS181

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Arpit Rao

First Author: Arpit Rao

First Author: Benedito A. Carneiro

First Author: Mehmet Asim Bilen